ClinicalTrials.gg
TerminatedNCT02428231TITRATIONUpdated May 5, 2017Results posted

Tecfidera Slow-Titration Study

A Phase 3 interventional study of dimethyl fumarate in Multiple Sclerosis, sponsored by Biogen. Terminated at 20 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. Dimethyl Fumarate · Multiple Sclerosis.

Enrollment
14th of 22
62 · median 86
Started
2015
with 6 others
Phase 3
9 of 22
1 open now
Registered
12th of 22
by date
Lead sponsor
17 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, this one is the 14th largest by enrollment, is one of 7 that started in 2015, is one of 9 in phase 3, and was the 12th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis is open now. Recruiting first, the newest first:

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, or all of them as a file.
02

Study summary

The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF [Tecfidera])-related gastrointestinal (GI) adverse events (AEs) in participants with multiple sclerosis (MS). The secondary objective of this study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the average severity and duration of GI symptoms over 12 weeks of DMF treatment in this study population.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of MS consistent with locally labeled indication for DMF
  • No prior treatment with DMF
  • Female subjects of who are not surgically sterile and male subjects must practice effective during their participation in the study
  • Have had a recent complete blood count (CBC), including lymphocyte count, that does not preclude participation in the study, in the judgement of the investigator

Key Exclusion Criteria:

  • Have a recent history or ongoing GI illness (e.g., peptic ulcer, irritable bowel syndrome) or any other current condition with GI signs and symptoms (e.g., nausea, vomiting, abdominal pain, or diarrhea) that may interfere with assessment of study endpoints
  • Have other major comorbid conditions that preclude participation in the study, as determined by the investigator
  • Participant is pregnant, breastfeeding, or planning a pregnancy during the study period
  • Are receiving concomitant disease-modifying therapies for MS including, but not limited to, natalizumab, interferon beta, glatiramer acetate, fingolimod, alemtuzumab, teriflunomide, or laquinimod at screening
  • History of severe allergic or anaphylactic reactions or known drug
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    Standard Treatment (One-Week Titration)

    120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks

    Drug: dimethyl fumarate

  • Experimental
    Slow Up-Titration (Six-Week Titration)

    120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks

    Drug: dimethyl fumarate

Interventions

  • Participants will be dosed twice daily for 12 weeks.

    Also known as: DMF, Tecfidera, BG00012

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With a Worsening in Severity of Gastrointestinal (GI) Adverse Events (AEs) on the Gastrointestinal Symptom Rating Scale (GSRS)

    The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity.

    Time frame: from Week 2 (Baseline) to Week 14

Secondary outcomes

  1. Average Change From Baseline in GSRS Scores During DMF Treatment

    Average change from baseline in GSRS scores over the 12 weeks of DMF treatment as measured by the total change in GSRS scores from baseline divided by the total number of days with GSRS scores recorded. The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms.

    Time frame: Week 2 (Baseline), Week 14

  2. Time to First Worsening From Baseline in GSRS Score

    The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity.

    Time frame: Week 2 (Baseline), Week 14

  3. Time to Recovery to Baseline From Last Occurrence of Worst GSRS Score

    The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity.

    Time frame: Week 2 (Baseline), Week 14

  4. Average Change From Baseline in GSRS Scores to the End of Weeks 4, 6, 8, 10, 12, and 14

    Average change from baseline to end of DMF treatment in the GSRS. The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms.

    Time frame: Week 2 (Baseline), Weeks 4, 6, 8, 10, 12, 14

07

Results

Posted May 5, 2017
Limitations and caveats
The Sponsor decided to terminate the study as a result of an evaluation of ongoing development programs.

Participant flow

Participant flow — Overall Study
MilestoneStandard Treatment (One-Week Titration)Slow Up-Titration (Six-Week Titration)
Started3032
Completed1715
Not completed1317
Withdrew: Other1016
Withdrew: Required symptomatic therapy01
Withdrew: Adverse event30

Outcome measures

PrimaryProportion of Participants With a Worsening in Severity of Gastrointestinal (GI) Adverse Events (AEs) on the Gastrointestinal Symptom Rating Scale (GSRS)

The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity.

Time frame:
from Week 2 (Baseline) to Week 14

No measurements were reported for this outcome.

SecondaryAverage Change From Baseline in GSRS Scores During DMF Treatment

Average change from baseline in GSRS scores over the 12 weeks of DMF treatment as measured by the total change in GSRS scores from baseline divided by the total number of days with GSRS scores recorded. The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms.

Time frame:
Week 2 (Baseline), Week 14

No measurements were reported for this outcome.

SecondaryTime to First Worsening From Baseline in GSRS Score

The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity.

Time frame:
Week 2 (Baseline), Week 14

No measurements were reported for this outcome.

SecondaryTime to Recovery to Baseline From Last Occurrence of Worst GSRS Score

The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity.

Time frame:
Week 2 (Baseline), Week 14

No measurements were reported for this outcome.

SecondaryAverage Change From Baseline in GSRS Scores to the End of Weeks 4, 6, 8, 10, 12, and 14

Average change from baseline to end of DMF treatment in the GSRS. The GSRS is a weekly recall scale to rate the severity of GI symptoms in participants. It was modified for daily recall in this study. GSRS is a rating scale consisting of 15 items for assessment of GI symptoms (see Appendix 1). Items are scored for intensity on a 7-grade Likert scale, defined by descriptive anchors such that 0 = none, 1 = minor, 2 = mild, 3 =moderate, 4 = moderately severe, 5 = severe, and 6 = very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 0 to 6; a score of 0 indicates that no symptoms are present, and a score of 6 indicates the worst possible degree of all symptoms.

Time frame:
Week 2 (Baseline), Weeks 4, 6, 8, 10, 12, 14

No measurements were reported for this outcome.

Adverse events

Collected over From start of study through Week 14 plus 2 weeks (±5 days) follow-up. Serious events were collected from time of informed consent and non-serious events were collected from the first dose and throughout the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard 1-Week Titration Arm—2/30 (6.7%)18/30 (60%)
6-Week Titration Arm—1/32 (3.1%)14/32 (43.8%)
Most frequent serious events
Most frequent serious events
EventStandard 1-Week Titration Arm6-Week Titration Arm
Gastrointestinal infectionInfections and infestations1/300/32
Hip fractureInjury, poisoning and procedural complications1/300/32
ArthralgiaMusculoskeletal and connective tissue disorders0/301/32
OsteoarthritisMusculoskeletal and connective tissue disorders0/301/32
Most frequent other events
Most frequent other events
EventStandard 1-Week Titration Arm6-Week Titration Arm
FlushingVascular disorders7/306/32
HeadacheNervous system disorders2/304/32
NasopharyngitisInfections and infestations3/303/32
Multiple sclerosis relapseNervous system disorders3/301/32
RashSkin and subcutaneous tissue disorders3/301/32
Gastroenteritis viralInfections and infestations1/303/32
Abdominal pain upperGastrointestinal disorders2/300/32
CystitisInfections and infestations2/302/32
PruritusSkin and subcutaneous tissue disorders2/301/32
Back painMusculoskeletal and connective tissue disorders1/302/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Standard Treatment (One-Week Titration)Slow Up-Titration (Six-Week Titration)Total
Mean45.5 ± 11.7742.5 ± 11.1244.0 ± 11.45
Sex: Female, Male
Sex: Female, Male(Participants)Standard Treatment (One-Week Titration)Slow Up-Titration (Six-Week Titration)Total
Female222143
Male81119
08

Study locations

20 sites
  • Research Site
    Gilbert, Arizona, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Long Beach, California, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Avon, Indiana, United States
  • Research Site
    Franklin, Indiana, United States
  • Research Site
    Overland Park, Kansas, United States
  • Research Site
    Lewiston, Maine, United States
  • Research Site
    Asheville, North Carolina, United States
  • Research Site
    Cary, North Carolina, United States
  • Research Site
    Charlotte, North Carolina, United States
  • Research Site
    Wilmington, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Wenatchee, Washington, United States
  • Research Site
    Leuven, Belgium
  • Research Site
    Wilrijk, Belgium
  • Research Site
    Prague, Czech Republic
  • Research Site
    Merano, Bolzano, Italy
  • Research Site
    Montichiari, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Dec 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2015
First posted
Apr 28, 2015
Start
Apr 2015
Primary completionActual
Dec 2015
CompletionActual
Jan 2016
Results first posted
May 5, 2017
Last update
May 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02428231
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 28, 2015
Start date
Apr 2015
Primary completion
Dec 2015
Completion
Jan 2016
Results posted
May 5, 2017
Last update
May 5, 2017

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion